SIRT6型
锡尔图因
乙酰化
癌症研究
福克斯A2
西妥因1
癌变
HDAC1型
生物
化学
癌症
组蛋白脱乙酰基酶
转录因子
组蛋白
生物化学
下调和上调
遗传学
基因
作者
Kaiqiang Zhao,Mingyue Zheng,Zezhuo Su,Shrestha Ghosh,Chao Zhang,Wen‐Zhao Zhong,Joshua W. K. Ho,Guoxiang Jin,Zhongjun Zhou
出处
期刊:Cell Reports
[Elsevier]
日期:2023-08-01
卷期号:42 (8): 112939-112939
被引量:3
标识
DOI:10.1016/j.celrep.2023.112939
摘要
Mammalian sirtuin 6 (SIRT6) regulates a spectrum of vital biological processes and has long been implicated in the progression of cancer. However, the mechanisms underlying the regulation of SIRT6 in tumorigenesis remain elusive. Here, we report that the tumor-suppressive function of SIRT6 in non-small cell lung cancer (NSCLC) is regulated by acetylation. Specifically, males absent on the first (MOF) acetylates SIRT6 at K128, K160, and K267, resulting in a decreased deacetylase activity of SIRT6 and attenuated SIRT6 tumor-suppressive function in NSCLC. Mechanistically, MOF-mediated SIRT6 acetylation hinders the interaction between SIRT6 and transcriptional factor FOXA2, which in turn leads to the transcriptional activation of ZEB2, thus promoting NSCLC progression. Collectively, these data indicate an acetylation-dependent mechanism that modulates SIRT6 tumor-suppressive function in NSCLC. Our findings suggest that the MOF-SIRT6-ZEB2 axis may represent a promising therapeutic target for the management of NSCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI